Audio long read: Will blockbuster obesity drugs revolutionize addiction treatment?
Researchers are investigating whether GLP-1 drugs can help blunt cravings for nicotine, alcohol and opioids.
Nature Podcast · [email protected]
Audio is streamed directly from the publisher (sphinx.acast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Anecdotal stories suggesting that weight-loss drugs can help people shake long-standing addictions have been spreading fast in the past few years, through online forums, weight-loss clinics and news headlines. And now, clinical data are starting to back them up.
Over a dozen randomized clinical studies testing whether GLP-1 drugs like Ozempic can suppress addiction are now under way, and neuroscientists are working out how these weight-loss drugs act on brain regions that control craving, reward and motivation.
Scientists warn that the research is still in its early stages, but some researchers and physicians are excited, as no truly new class of addiction medicine has won approval from regulators in decades.
This is an audio version of our Feature: Will blockbuster obesity drugs revolutionize addiction treatment?
Hosted on Acast. See acast.com/privacy for more information.